Veraxa Biotech AG - Post de-SPAC reported cash from operations of $0.00M and free cash flow of $0.00M for the quarter ended Dec 2025. This cash flow statement covers 2 quarters of results from Dec 2024 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Dec2024 | Dec2025 |
|---|---|---|
| Operating Activities | ||
| Cash from OperationsCash from Ops. | 0.00M | |
| Change in Working Capital | ||
| Change in Accured ExpensesChange Accured Exp. | 0.02M | |
| Financing Activities | ||
| Cash from Financing ActivitiesCash from Financing | 0.13M | |
| Additional items | ||
| Beginning Cash Balance | 12.96M | 6.71M |
| Free Cash FlowFCF | 0.00M | |
| Net Cash FlowNCF | 0.13M |